Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

Recent News and Articles on the Keywords: abnormal + induces + preleukemic  Related to the article below (Last Update: 12/1/2008)

News results: Standard Version | Text Version | Image Version

Browse Top Stories Recent Last hour Last day Past week Past month Archives All dates Blogs News Alerts RSS | Atom About Feeds Your search - abnormal + induces + preleukemic - did not match any documents. Suggestions: Make sure all words are spelled correctly. Try different keywords. Try more general keywords. Try fewer keywords. Try Google Blog Search. Also, you can browse today's headlines on the Google News homepage.

Recent News and Articles on the Keywords: 0.36 + web  Related to the article below (Last Update: 8/7/2008)

Salem Communications Announces Second Quarter 2008 Total Revenue ... MarketWatch - ... net of tax $ - $ 0.03 $ - $ 0.09 Basic income per share after discontinued operations $ 0.12 $ 0.15 $ 0.25 $ 0.36 Diluted income per share before ...SALM 2009 Chevrolet Traverse is the Most Aerodynamic Lambda Automobile Magazine - According to the General, Buick's Enclave and Saturn's Outlook each has a higher drag coefficient of 0.36, while the GMC Acadia's 0.34 drag coefficient is ... Ashford Hospitality Trust Reports Second Quarter Results MarketWatch - Additional information can be found on the Company's web site at www.ahtreit.com. Certain statements and assumptions in this press release contain or are ...AHT Alliant Energy Announces Second Quarter 2008 Results PR Newswire (press release), NY - Aug 6, 2008 An archive of the webcast will be available on the Company's Web site at http://www.alliantenergy.com/investors for 12 months. Alliant Energy is the parent ...LNT - KIDS Amkor Reports Second Quarter 2008 Results MarketWatch - Aug 5, 2008 This call is being webcast by Thomson Financial and can be accessed at Amkor's web site at www.amkor.com. You may also access the call by dialing ...AMKR Pre-Market: Market likely to remain rangebound Myiris.com, India - China`s Shanghai Composite rose 9.82 points, or 0.36%, to trade at 2729.19. South Korea`s Kospi index dropped 12.87 points, or 0.82%, to trade at 1565.84. ... Gerdau SA Announces 1st Half 2008 Results CNW Telbec (Communiqu?s de presse), Canada - Metalurgica Gerdau SA shareholders will receive R$ 0.60 per share and Gerdau SA shareholders R$ 0.36 per share. -- EBITDA reaches R$ 4.7 billion in the 1st ...GGB - SAO:GOAU4 Cisco Reports Fourth Quarter and Fiscal Year 2008 Earnings CNNMoney.com - Aug 5, 2008 We believe we are entering the next phase of the Internet as growth and productivity will center on collaboration enabled by networked Web 2.0 technologies. ... Covidien Reports Third-Quarter 2008 Results MarketWatch all 413 news articles »  CSCO National Retail Properties, Inc. Q2 2008 Earnings Call Transcript Seeking Alpha, NY - Aug 4, 2008 These stores are generally smaller units, and in total they represent about 0.36% of our current annual base rent. Our guidance does take into affect the ...NNN Nexstar Broadcasting Group Reports Record Second Quarter Results Trading Markets (press release), CA - Aug 5, 2008 A live audio webcast of the call will be accessible to the public on Nexstar's web site, www.nexstar.tv. A recording of the webcast will subsequently be ... W&T Offshore Reports Record Second Quarter Earnings Per Share of ... PR Newswire (press release) all 439 news articles »  WTI - NXST

CBFB-SMMHC, an oncoprotein, induces abnormal preleukemic blood cell progenitors

Researchers have developed a novel mouse model for leukemia that reveals critical information about the mechanisms involved in leukemia progression and provides a model system for evaluation of new drugs for treatment of leukemia.

The research has utilized a technique that allows induction and study of a key oncoprotein in adult mice.
Previously, it was difficult to investigate this oncoprotein in the mouse, as the expression of this gene is associated with embryonic lethality, or death of the developing mouse in utero.

Acute myeloid leukemia ( AML ) can arise from genetic alterations in the bone marrow cells that give rise to blood cells. One fusion oncoprotein that is present in about 12% of human AML cases and is known to interfere with the process of normal blood cell development is called CBFB-SMMHC. Thus far, this protein has been very difficult to study in mouse models, as its expression causes embryonic lethality.

Lucio H. Castilla from the Program in Gene Function and Expression at the University of Massachusetts Medical School and colleagues created a conditional mouse model to analyze the preleukemic effects of CBFB-SMMHC on blood cell production and acute myeloid leukemia development in adult mice. The mouse model enabled the researchers to selectively turn on expression of CBFB-SMMHC in adult mice, thereby avoiding embryonic lethality of expression of this gene, and then study the effects.

The researchers found that CBFB-SMMHC induction was associated with a reduction of immature blood cells in the bone marrow and with the appearance of abnormal progenitor cells that are leukemic precursors. Mice expressing CBFB-SMMHC developed acute myeloid leukemia with a median latency of approximately five months, with the time of disease onset varying with the number of abnormal cells in the bone marrow. Interestingly, additional studies showed that the blood stem cell precursors that expressed CBFB-SMMHC were maintained at normal levels for long periods of time, but their ability to differentiate into multiple types of blood cells was severely compromised.

The researchers conclude that some leukemia fusion proteins that interfere with differentiation of blood cells may maintain normal numbers of blood stem cell precursors, but that these precursors may not be able to repopulate the blood adequately.
In addition, such fusion proteins may induce formation of abnormal precursor cells that are targets for development of acute myeloid leukemia, essentially existing as cancer causing "time bombs" in the bone marrow.

According to Castilla, " this model will be key for the study of early target genes in blood cell progenitors and the in vivo validation of cooperating oncogenes, as well as for the evaluation of candidate drugs for improved treatment of acute myeloid leukemia."

Source: Cancer Cell, 2006